Search

Displaying results 3241 - 3250 of 10000 in total
  1. Drug

    Ieramilimab

    go.drugbank.com/drugs/DB16419
    Investigational

    Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

  2. Drug

    Volagidemab

    go.drugbank.com/drugs/DB16421
    Investigational

    Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).

  3. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  4. Drug

    Rintatolimod

    go.drugbank.com/drugs/DB16425
    Investigational

    Synonyms: POLY(5')-INOSINYL-(3'->) DUPLEX WITH POLY(DODECAKIS(3')-CYTIDYLYL-(5'->)3')-URIDYLYL-(5'->), 5'-INOSINIC ACID, HOMOPOLYMER, COMPLEX WITH 5'-CYTIDYLIC ACID POLYMER WITH 5'-URIDYLIC ACID (1:1)Categories: Poly C, Poly I
  5. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell

  6. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence[L30543].

  7. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553]. … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].

  8. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology.

  9. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.

  10. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … In rats, toxicity studies have so far shown favourable safety for this vaccine[L30653, L30658], Phase 1 trial is currently ongoing in Taiwan (NCT04545749).